glp 1 renal benefits GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes Real-World Evidence for GLP-1 Receptor

Delivering immune stimulating antigens to specific areas of the gut, using proprietary encapsulation technologies, with the objective of activating protective mucosal immunity

May help reduce cravings

Breaking a weight-loss plateau on GLP-1

Atherosclerosis is a chronic inflammatory disease characterized by lipid and inflammatory cell deposits in the inner layer of large- and medium-sized elastic and muscular arteries

The Risks: Unknown ingredients and contamination Incorrect dosages and life-threatening side effects No regulatory oversight or safety data Why This Is Critical: Patients are bypassing pharmacies and getting injections from sketchy online vendors This undermines real GLP1 therapies and can lead to serious harm As healthcare professionals, we must: Ask patients about the source of their medications Report adverse reactions to MedWatch Educate our patients about safe access and real prescriptions Lets advocate for ethical prescribing and responsible patient care in the GLP1 era

Food and Drug Administration (FDA) approved Wegovy (the brand name for once-weekly Semaglutide 2.4 mg injection) for chronic weight management